nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Browsing articles in "Alzheimer's/Other Dementias"

 

FDA Authorizes Marketing for New Test to Improve Diagnosis of Alzheimer’s Disease
May 9, 2022   

The U.S. Food and Drug Administration (FDA) approved marketing authorizationnfor anst in vitro diagnostic test for the early detection of amyloid plaques, one of the pathological hallmarks associated with Alzheimer's adises. The test is the first FDA-authorized in vitro diagnostic test in the U.S. to aid in the assessment of Alzheimer’s disease and other causes of cognitive decline...
 Continue reading (Members only)
Impact of Neuropsychiatric Symptoms in Alzheimer’s Disease
March 4, 2022   

Neuropsychiatric symptoms, including depression, apathy, and anxiety, are common among individuals with Alzheimer’s dementia. It is not yet clear the relationship among NPS, cognitive symptoms, and Alzheimer’s dementia neuropathology (which includes amyloid beta deposits, neurofibrillary tangles composed of hyperphosphorylated tau, and neurodegeneration). In this article...
 Continue reading
ADHD and Alzheimer’s Disease Across Generations
September 25, 2021   

Due to previous conflicting results regarding the association between attention-deficit hyperactivity disorder (ADHD) and Alzheimer’s disease (AD), a recent nationwide cohort study evaluated their link across generations. Index persons (N=2,132,929) born in Sweden were linked to their biological relatives: 4,246,182 index person-parent pairs....
 Continue reading (Members only)
Potential Therapeutic Option For Treatment Of Severe Dementia-Related Psychosis
August 2, 2021   

Pimavanserin is an oral serotonin 5HT2A inverse agonist and antagonist approved for the treatment of Parkinson’s disease psychosis. A phase 3, double-blind, randomized, placebo-controlled discontinuation trial examined efficacy of pimavanserin in patients with psychosis related to various dementia...
 Continue reading
Short Sleep Tied to Increased Dementia Risk
May 4, 2021   

In a recent study, the association between sleep dysregulation and dementia was examined. Data from 7,959 participants of the Whitehall II study was analyzed for sleep duration and the incidence of dementia, using a 25-year follow-up. A total of...
 Continue reading (Members only)
Psychotropic Polypharmacy Prevalent in Patients With Dementia
March 25, 2021   

Dementia is increasingly prevalent as the population ages. In addition to memory deficits, patients with dementia often exhibit other neuropsychiatric symptoms that can be disturbing to caregivers and increase the likelihood of institutionalization. It is therefore not uncommon for patients with dementia to be prescribed psychotropic agents despite...
 Continue reading (Members only)
Apathy an Early Marker of Frontotemporal Dementia
February 1, 2021   

Frontotemporal dementia is a disorder resulting from accumulation of pathological proteins such as phosphorylated tau and transactive response DNA binding protein of 43 kDA in the brain. Mutations in various genes, including microtubule associated protein tau...
 Continue reading (Members only)
Systolic Orthostatic Hypotension Tied to Dementia Risk
August 21, 2020   

A recent study examined whether orthostatic hypotension and visit-to-visit blood pressure postural changes variability are associated with incident dementia. The study involved 2,131 people aged 73 years old on average. Repeatedly over a period of five years, researchers A recent study examined whether orthostatic hypotension and visit-to-visit blood pressure postural changes variability are associated with incident dementia. The study involved 2,131 people aged 73 years old on average. Over a period of five years, researchers...
 Continue reading (Members only)
Biogen Submits Application for US Approval for Alzheimer Drug
July 27, 2020   

Biogen completed the submission of a Biologics License Application for its monoclonal antibody aducanumab to the US Food and Drug Administration for the treatment of Alzheimer’s disease...
 Continue reading (Members only)
FDA Approves First Drug to Image Tau Pathology in Patients Being Evaluated for Alzheimer’s Disease
June 15, 2020   

The US Food and Drug Administration has approved flortaucipir F18 injection, a diagnostic agent for adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease ...
 Continue reading
1234
Top of Page